PARP Inhibitor Market is driven by rising incidence of breast and ovarian cancer
The Parp Inhibitor market comprises drugs that hinder the activity of Poly (ADP-ribose) polymerase, or PARP for short. PARP is an enzyme involved in DNA repair. PARP inhibitors are mainly used for the treatment of cancers with defects in homologous recombination repair (HRR) genes like BRCA1 and BRCA2. This includes breast, ovarian, and prostate cancers. Effective utilization of PARP inhibitors can significantly improve prognosis for patients with such HRR-deficient cancers.
The Global Parp Inhibitor Market is estimated to be valued at US$ 7.20 Bn in 2024 and is expected to exhibit a CAGR of 8.8% over the forecast period 2024 to 2031.
Get More Insights on PARP Inhibitor Market https://articlescad.com/pa...
The Parp Inhibitor market comprises drugs that hinder the activity of Poly (ADP-ribose) polymerase, or PARP for short. PARP is an enzyme involved in DNA repair. PARP inhibitors are mainly used for the treatment of cancers with defects in homologous recombination repair (HRR) genes like BRCA1 and BRCA2. This includes breast, ovarian, and prostate cancers. Effective utilization of PARP inhibitors can significantly improve prognosis for patients with such HRR-deficient cancers.
The Global Parp Inhibitor Market is estimated to be valued at US$ 7.20 Bn in 2024 and is expected to exhibit a CAGR of 8.8% over the forecast period 2024 to 2031.
Get More Insights on PARP Inhibitor Market https://articlescad.com/pa...
09:18 AM - Mar 10, 2025 (UTC)
